Article
Bristol Myers' hopes for a CAR-T nod by year-end fade as COVID-19 delays FDA inspection
Rating:
0.0
Views:
68
Likes:
1
Library:
1
Bristol Myers Squibb's CAR-T regulatory path has been studded with FDA rejection and delays that now threaten to derail the company's original plan of an approval by the end of the year. As the agency pushes back a decision on liso-cel again due to COVID, Celgene investors' $9-apiece CVRs could be worthless soon.
Rate This Post
-
Education
-
Communication
-
Entertainment
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value